Skip to main content

Table 4 Prediction for mortality

From: One-year mortality and Periprosthetic infection rates after Total knee Arthroplasty in Cancer patients: a population-based cohort study

Ā 

Adjusted

sHRa(95%C.I.)

p-value

Cancer vs. Non-cancer

2.46 (1.71ā€“3.52)

<.0001

Comorbidities

ā€ƒMyocardial infarct

1.98 (0.98ā€“3.99)

0.0557

ā€ƒcongestive heart failure

1.56 (0.98ā€“2.49)

0.0632

ā€ƒperipheral vascular

0.53 (0.17ā€“1.64)

0.2717

ā€ƒcerebrovascular disease

0.83 (0.57ā€“1.20)

0.3263

ā€ƒdementia

0.97 (0.40ā€“2.34)

0.9477

ā€ƒchronic lung disease

1.26 (0.74ā€“2.17)

0.3943

ā€ƒconnective tissue disease

1.23 (0.65ā€“2.32)

0.5240

ā€ƒUlcer

1.31 (0.67ā€“2.56)

0.4305

ā€ƒchronic liver disease

1.43 (0.32ā€“6.48)

0.6403

ā€ƒDiabetes

1.04 (0.67ā€“1.63)

0.8608

ā€ƒdiabetes with end organ damage

1.24 (0.55ā€“2.79)

0.5993

ā€ƒHemiplegia

1.80 (0.52ā€“6.24)

0.3566

ā€ƒmoderate or severe kidney disease

1.84 (0.64ā€“5.32)

0.2614

ā€ƒModerate or severe liver disease

ā€“

Ā 

ā€ƒAIDS

ā€“

Ā 

Metastasis

1.17 (0.68ā€“2.01)

0.5754

Ā 

ā€“

Ā 
  1. sHRa: subdistribution hazard ratio